SEIS investment opportunity · Sophisticated & high-net-worth investors
The compliance technology layer for European aesthetics.
A large, regulated, fast-growing market with no compliance-first platform for cross-border B2B procurement. Pharmiva is building it — connecting clinics to verified suppliers across Germany, the Netherlands, Poland and the United Kingdom.
HMRC SEIS Advance Assurance applied for · Subscription documents via SeedLegals
The opportunity
A large, regulated market with no compliance-first platform
European medical aesthetics is growing fast and professionalising under tightening regulation — yet clinics still have no compliant, cross-border way to procure injectables and devices. The backdrop is public; the platform is missing.
The problem
Clinics buy in a fragmented, unverified market
European medical aesthetics is professionalising under tightening regulation — yet clinics still have no compliant, cross-border way to procure injectables and devices.
Fragmented supply
Clinics source from unverified suppliers via phone, trade shows and personal contacts — with no compliance layer in the procurement chain.
No EU-scale platform
There is no single, always-on marketplace where clinics across multiple markets can compare supplier-verified products and prices.
Prescription-only risk
Botulinum toxin is a prescription-only medicine across the EU; verifying prescriber credentials at the point of order is largely manual.
Grey-market exposure
Without licensed, transparent cross-border supply, clinics are exposed to grey-market imports and the regulatory risk that follows.
The approach
A compliance-first marketplace, built on licensed infrastructure
Pharmiva is the technology layer for compliant B2B aesthetic procurement, operating through licensed wholesale infrastructure. Clinics get one verified, auditable channel; suppliers get reach. Compliance is built into the order flow, not bolted on.
Verified marketplace
A multi-supplier catalogue with clinic onboarding, KYC and verified products — one channel instead of many.
Prescriber verification
A telemedicine layer confirms prescriber credentials before prescription-only products are dispatched.
Compliance & audit
Orders flow through licensed infrastructure with full audit trail and regulatory reporting end-to-end.
The detail of how Pharmiva's platform and its licensed infrastructure fit together — the structure, the defensibility, and why it is difficult to replicate — is set out in the investor deck, available to qualifying investors on request.
Why now
Regulation is professionalising the sector
Every regulatory step rewards an operator built around compliance from day one. Tightening rules turn non-compliant supply chains into licence risk — and increase the value of a platform that makes compliance frictionless. Compliance is the moat, not the cost.
The investment
Invest in Pharmiva under SEIS
The raise is structured under the Seed Enterprise Investment Scheme, with attractive reliefs for eligible UK investors. HMRC Advance Assurance has been applied for; SEIS3 certificates are issued after the qualifying trading period.
Full investment terms, valuation rationale, use of proceeds, roadmap and the complete risk summary are set out in the investor deck and Information Memorandum — released to investors who qualify and register below. SEIS reliefs depend on individual circumstances and HMRC approval, and may be withheld or withdrawn.
The features
The core platform
Specialised marketplace
Purpose-built platform for supplements and aesthetics products.
Verified vendor onboarding
Structured onboarding to enhance vendor credibility and trust.
Advanced product discovery
Optimised search and filtering for efficient product discovery.
Vendor growth tools
Analytics tools to improve vendor performance and conversions.
Multi-revenue marketplace
Commission, subscriptions, and advertising revenue streams integrated.
Trust & transparency framework
Clear product information supporting confident purchasing decisions.
Scalable, compliance-aware architecture
Built for sustainable growth within evolving regulatory environments.
Flexible investment
Invest at your level
Seed investor
- Early access entry valuation
- Full SEIS eligibility (subject to qualification)
- Shareholder certificate and formal allocation
- Quarterly investor updates
- Priority access to future funding rounds
Growth investor
- Enhanced allocation within the raise
- Full SEIS eligibility (subject to qualification)
- Direct investor call access with founders
- Bi-annual strategic progress briefings
- Priority participation in future rounds
Strategic investor
- Larger allocation with structured participation
- Full SEIS eligibility (subject to qualification)
- Direct access to leadership team
- Involvement in key growth discussions
- Early visibility on expansion and exit strategy
Our process
A step-by-step investment process
Register your interest
Complete the short investor form to express interest in the Pharmiva SEIS raise and receive the investment pack, including the deck, financials, and key terms.
Review and confirm
Assess the opportunity, conduct your due diligence, and speak directly with the founding team to clarify valuation, allocation, and SEIS eligibility before confirming your commitment.
Complete your investment
Sign the subscription documents, transfer funds, and receive confirmation of your shareholding along with SEIS documentation and ongoing investor updates.
FAQ
Got questions? We've got answers
What is Pharmiva?
Pharmiva is a compliance-first B2B marketplace connecting aesthetic clinics to verified suppliers of injectables and medical devices across the UK, Germany, the Netherlands, and Poland — with compliance built directly into the order flow.
Why does Pharmiva exist?
Aesthetic clinics currently source products through fragmented, unverified channels. Pharmiva replaces that with a single, auditable procurement platform operating through licensed wholesale infrastructure.
How does Pharmiva handle prescription-only products?
A built-in telemedicine layer verifies prescriber credentials before any prescription-only product is dispatched, removing the manual checks clinics currently rely on.
How does Pharmiva protect clinics from grey-market risk?
All suppliers undergo KYC and vendor verification. Every order flows through licensed infrastructure with a full audit trail, giving clinics a defensible, regulatory-compliant procurement record.
What types of products are available?
Injectables and medical aesthetic devices sourced from verified, licensed suppliers — all carrying full compliance documentation.
What is the current investment raise?
Pharmiva is raising £250,000 under SEIS at a £2.25 million pre-money valuation, representing 10% equity.
What SEIS tax reliefs are available?
Eligible UK investors can receive 50% income tax relief, CGT-free gains after 3 years, up to 100% IHT relief after 2 years, and a maximum loss exposure of around 38.5p per £1 invested. Reliefs depend on individual circumstances and HMRC approval.
How do I invest?
Register your interest on the website to receive the full investor deck and Information Memorandum. This raise is open to sophisticated and high-net-worth investors only.
Request access
Request the investor deck
The full opportunity — deck, Information Memorandum and terms — is a financial promotion directed only at qualifying investors. Register your interest and confirm your investor status to receive it.
Register your interestGet in touch
Speak with the team
Have questions or need guidance on the raise? Connect with our team for tailored support.
261 Bolton Road, 2839 Davenport House, Bury, United Kingdom, BL8 2NZ